Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

Although irinotecan 350 mg m(−2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). This study assessed the optimal dosing strategy for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2005
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361950/
https://ncbi.nlm.nih.gov/pubmed/15756271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602462
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados